ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Down 45.7% in March

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) saw a significant decline in short interest during the month of March. As of March 15th, there was short interest totalling 646,000 shares, a decline of 45.7% from the February 29th total of 1,190,000 shares. Based on an average trading volume of 2,630,000 shares, the short-interest ratio is currently 0.2 days. Currently, 16.9% of the shares of the stock are sold short.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of ZyVersa Therapeutics in a research note on Tuesday.

ZyVersa Therapeutics Stock Down 3.5 %

Shares of NASDAQ ZVSA opened at $0.75 on Friday. The company has a 50-day moving average of $0.74 and a two-hundred day moving average of $2.07. ZyVersa Therapeutics has a 1-year low of $0.50 and a 1-year high of $90.65.

Institutional Investors Weigh In On ZyVersa Therapeutics

A hedge fund recently bought a new stake in ZyVersa Therapeutics stock. Walleye Capital LLC purchased a new position in shares of ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 980,568 shares of the company’s stock, valued at approximately $128,000. Walleye Capital LLC owned about 3.17% of ZyVersa Therapeutics at the end of the most recent reporting period. 3.91% of the stock is currently owned by institutional investors.

About ZyVersa Therapeutics

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company engages in the development of VAR 200, a cholesterol efflux mediator, which is in Phase 2a clinical trial to the treatment of multiple renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic nephropathy; and IC 100, a monoclonal antibody inflammasome ASC inhibitor that is in preclinical stage for treatment of multitude of inflammatory diseases.